الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 111 |  |  |
| | | from | 111 | | |
Abstract
Hepatitis C Virus (HCV), first identified in 1989, is an RNA virus, which is a major health problem in Egypt with its prevalence estimated to be 25% among the general population in 2015. The prevalence of HCV infection among haemodialys is patients varies from country to country and from one center to another, Egypt is one of the countries with high HCV prevalence. In Egypt, the prevalence of HCV in haemodialysis patients was 50.7%. This study was conducted on HCV patients who undergo haemodialysis and patients with normal renal functions who had taken Qurevo in different dialysis units in Assuit City and who attending to Assuit hepatic Institute to assess the percentage of complete recovery or clearance of the virus, assess the percentage of failure or relapse of treatment and assess the side effects of the drug between them . After obtaining hospital ethics committee approval and written informed consent from the patient at the period from May 2017 to May 2018. The study included 47 patients with chronic HCV infection on regular dialysis (study group) and 50 patients with chronic HCV infection (control group).